We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ADAP market cap is 937.75M. The company's latest EPS is USD -0.1676 and P/E is -5.37.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 7.01M | 11.03M | 47.6M | 5.13M | 7.32M |
Operating Income | -45.38M | -27.18M | 1.55M | -22.94M | -46.3M |
Net Income | -41.42M | -29.25M | 1.04M | -21.39M | -45.6M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 59.51M | 1.12M | 3.96M | 6.15M | 27.15M |
Operating Income | -98.61M | -138.62M | -133.58M | -157.85M | -166.4M |
Net Income | -91.56M | -137.17M | -130.09M | -158.09M | -165.46M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 332.2M | 328.92M | 288.08M | 342.98M | 296.64M |
Total Liabilities | 218.87M | 247.04M | 204.21M | 216.33M | 208.51M |
Total Equity | 113.34M | 81.88M | 83.88M | 126.65M | 88.13M |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 282.95M | 181.54M | 451.14M | 469.55M | 328.92M |
Total Liabilities | 29.85M | 57.91M | 109.92M | 263.59M | 247.04M |
Total Equity | 253.1M | 123.64M | 341.23M | 205.96M | 81.88M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -143.81M | -141.77M | -37.28M | -81.05M | -126.2M |
Investing | 68.19M | 89.14M | 48.34M | 51.04M | 108.34M |
Financing | 11.46M | 12.87M | 196k | 210k | 806k |
Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -104.24M | -112.51M | -53.59M | 10.73M | -141.77M |
Investing | -17.6M | 94.95M | -278.92M | 75.8M | 89.14M |
Financing | 102.69M | 366k | 340.05M | 3.29M | 12.87M |
Market Cap | 937.75M |
Price to Earnings Ratio | -5.37 |
Price to Sales Ratio | 32.73 |
Price to Cash Ratio | 8.23 |
Price to Book Ratio | 10.85 |
Dividend Yield | - |
Shares Outstanding | 987.11M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0.03 (2.66%) |
Company Name | Adaptimmune Therapeutics PLC |
Address |
60 jubilee avenue oxfordshire OX14 4RX |
Website | https://www.adaptimmune.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions